Genexine제넥신
095700 · KOSDAQ · ₩095700 · 제넥신
- Market cap
- ₩99B
- Enterprise value
- ₩188B
- P/E
- —
- P/B
- 0.5×
- Dividend yield
- 0.0%
- ROE
- −16.1%
- Net margin
- −650.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−71.1% from the high
₩2,140Today: ₩2,165 – ₩2,265₩7,490
Returns
- 1W−12.0%
- 1M−19.1%
- 3M−7.5%
- 6M−60.1%
- YTD−53.8%
- 1Y−58.1%
- Volume today
- 85,983
- 0.4× the 20-day average
- Traded today
- ₩188M
- Listed shares
- 45,540,494
- EPS (12 months)
- −₩709
- Earnings yield −32.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 38 of 100 (50 is a normal day for this stock).
- SentimentNegativeNews: Filings about new share issues and amendments tend to weigh on sentiment for existing holders. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-21.8% over the last month; the price is below its 20-day average.
- News impactHigh6 news items and filings in two weeks; 2 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Genexine stock overview
Genexine (제넥신, KRX: 095700) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biopharmaceutical firm developing next-generation innovative drugs based on its proprietary hyFc fusion protein platform and DNA vaccine manufacturing technology. Its shares closed at ₩2,165 on Oct 29, 2026, down 3.78% on the day, giving it a market value of ₩99B.
Key facts
- Market cap
- ₩99B
- Sector
- Biotech & Pharma
- Latest price change
- −3.78%
- As of
- Oct 29, 2026
- Main business
- The company is a Korean biopharmaceutical firm developing next-generation innovative drugs based on its proprietary hyFc fusion protein platform and DNA vaccine manufacturing technology.
Quick answers about Genexine
- What does Genexine do?
- The company is a Korean biopharmaceutical firm developing next-generation innovative drugs based on its proprietary hyFc fusion protein platform and DNA vaccine manufacturing technology. Its products include long-acting protein therapeutics for conditions such as cancer, endocrine disorders, and immune diseases, as well as a DNA vaccine targeting HPV-related diseases. Following a merger with EPD Bio, it is also developing bioPROTAC targeted protein degradation candidates, with commercialization pursued mainly through partnerships and technology licensing with domestic and global pharmaceutical companies.
- What is the market cap of Genexine?
- The market capitalisation of Genexine was ₩99B at the close on Oct 29, 2026.
- Who are the largest shareholders of Genexine?
- According to the latest official filings, the largest reported holders are Seong Yeong-cheol (4.98%, as of Jan 20, 2025); Choi Jae-hyeon (3.71%, as of Oct 22, 2024); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.39%, as of Jul 31, 2026).
- When is the next earnings report from Genexine?
- Korean companies rarely announce results dates in advance. Based on when Genexine filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Genexine?
- Yes. The National Pension Service held 0.15% of Genexine shares as of Dec 31, 2023.
Company profile
The company is a Korean biopharmaceutical firm developing next-generation innovative drugs based on its proprietary hyFc fusion protein platform and DNA vaccine manufacturing technology. Its products include long-acting protein therapeutics for conditions such as cancer, endocrine disorders, and immune diseases, as well as a DNA vaccine targeting HPV-related diseases. Following a merger with EPD Bio, it is also developing bioPROTAC targeted protein degradation candidates, with commercialization pursued mainly through partnerships and technology licensing with domestic and global pharmaceutical companies.
Written by AI from the company's latest annual report.
- Korean name
- 제넥신
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 홍성준, 최재현
- Founded
- Jun 1999
- Listed
- Sep 2009
- Listed shares
- 45,540,494
- Fiscal year ends
- Month 12
- Website
- genexine.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Rights offering (paid-in capital increase) decisionOct 26, 2026
- Small Public Offering Performance ReportOct 26, 2026
- [Amended] Small-Scale Public Offering Disclosure Documents (Equity Securities)Oct 26, 2026
- Amended: Rights offering (paid-in capital increase) decisionOct 26, 2026
- Small-Scale Public Offering Disclosure Documents (Equity Securities)Oct 16, 2026
Titles in Korean until English translations are added.
Also known as: Genexine / 제넥신 / 095700 / KRX:095700
Source: KRX statistical information